⚕ GalenOps CRO console
← SITE015 (POL)

SITE015-0227

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE015 (POL) (Dr. Ito) · consented 2022-11-23
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 27); relationship: Y

mild assessed 2026-08-18

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-01-16 (study day 46); relationship: N

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 47); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: UNKNOWN; onset 2023-02-03 (study day 64); relationship: N

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-22 (study day 83); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-25 (study day 86); relationship: N; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-10 (study day 99); relationship: N

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-13 (study day 102); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.